DCVA and RegMed XB Community Meeting

Program

15:00 - 15:20	Walk in
15:20 - 15:30	Opening Bernard Mulder, CEO RegMed XB
15:30 - 16:10	Speaker Eliane Schutte, CEO Xeltis about the challenges of entering clinical development from a young company's perspective
16:10 - 16.15	Jolien Roos-Hesselink, Managing-Director DCVA
16:15 - 16:55	Speaker Prof. Dr. Yigal Pinto, Clinical Cardiologist about preparing for clinical research, both from an investigator's and a CMO's perspective
16:55 - 17:05	Farewell Tribute Marianne van der Steen, co-founder RegMed XB
16:55 - 17:05	Networking drinks

Speakers

Eliane Schutte is the CEO of Xeltis a clinical stage medtech company developing transformative implants that enable the natural creation of living and long lasting vessels and valves. Xeltis aims to meet the needs of patients and healthcare providers by offering self healing, non immunogenic implants that remain open, with a low risk of infection and a reduced need for surgical reintervention. The company recently
raised €44.5 million in a Series D2 round to fund its ongoing clinical development. Eliane will speak about the challenges of entering clinical development from a young company's perspective.

Prof. Dr. Yigal Pinto is a professor at the University of Amsterdam, where he leads the Department of Experimental Cardiology in conjunction with his clinical practice in heart failure. He has initiated and executed several prospective clinical trials on heart failure management. Based on 17 years of research within his group, Yigal founded Phlox Therapeutics, a preclinical stage biotech company that develops RNA based therapies for cardiac laminopathies and therapy resistant heart failure. Yigal will reflect on the insights he has gained in preparing for clinical research, both from an investigator's and a CMO's perspective.

Join the event to learn from our experts and discuss with your collegues during the networking drinks!

FULLY BOOKED: We're pleased to share that the upcoming event is now fully booked! Thank you all for the tremendous interest and enthusiasm. Due to the high demand, we've initiated a waiting list for those who still wish to participate. If you register now, you'll be added to this list.